INTRODUCTION
Cancer stem cells (CSCs) possess features that promote malignant potential, including cell differentiation, self-renewal, tumorigenicity, chemoresistance and metastasis [1] . Dick et al. first isolated CSCs from patients with acute myeloid leukemia, which have the ability to proliferate as hematopoietic stem cells and differentiate into leukemic cells [2, 3] . To date, CSCs have been isolated from solid breast, brain, lung, liver, mouth, ovary, prostate, and colon tumors. To identify breast CSCs, a subpopulation of primary cancer cells expressing markers of self-renewal and differentiation potential are isolated and tested for tumorigenicity in mouse xenograft models [4] .
Bapat et al. isolated two clones of ovarian cancer stem-like cells (CSLC) capable of sphere formation from ascites cultures [5] , whereas Zhang et al. used cell sorting to isolate CD44 and CD117 double-positive ovarian cancer-initiating cells from primary human tumors [6] . Using three human ovarian cancer cell lines and four clinical human primary ascites cell lines, Szotek et al. identified a verapamil-sensitive subpopulation that expressed breast cancer resistance protein 1 [7] . Regardless of the methods, either sphere formation or cell sorting, the yield of the cancer stem cells or cancer stem-like cells thus harvested is pretty low (less than 1%). Hence it takes tremendous efforts to collect an adequate amount of stem cells for study [5] . An easier method to enrich the cancer stem cells or cancer stem-like cells will facilitate the biological study of cancer stem cells.
In ovarian cancer cells SKOV3 and OVCAR3, originated from human ovarian cancer ascites cells, expression of either CD44, CD24 or CD133 markers is related to drug-resistance, a stem-like characteristics of cancer cells [8] [9] [10] . Yu et al. reported that cancer cells from ascites induced by SKOV3 cells possesses enhanced malignant characteristics, including a rapid growth rate, enhanced ability of colony formation, and a shortened survival of the host animals [11, 12] . The highly therapyresistant OVCAR3 was used for studying the mechanisms of drug-and radiation-resistance. Owing to the above biological characteristics, SKOV3 and OVCAR3 cells were used in our study for the enrichment of the stem-like cells.
In the literature, CD44 and CD133 expressions were risk factors for ovarian cancer metastasis and poor survival. The ascites cells with high CD44 and CD133 expressions, from ovarian cancer patients, displays more potentials for self-renewal and long-term proliferation [7, 8, 13, 14] . CD44 expression activates nanog protein, a stemness marker, which enhances chemoresistance in breast and ovarian cancer cells. Hence we attempted to enrich the cancer stem-like cell population by using CD 44, CD133 as selection markers.
In advanced cancer, proliferating CSC-like cells determine disease progression, prognosis, and chemoresistance [15] . We hypothesized that a small subpopulation of CSC-like malignant progenitor cells could be enriched from ascites induced in immunodeficient mice via the intraperitoneal inoculation of ovarian cancer cells (SKOV3 and OVCAR3 cells). These ascites CD133 +
44
+ cells exhibited similar proliferating cancer stemloids characteristics, such as proliferation, chemoresistance, and tumor progression [16] . Our stemlike cell enrichment method could facilitate biological studies of ovarian CSCs, target-drug discovery and studies in other cancer types.
RESULTS

SKOV-3 and OVCAR3 ascites cells exhibited malignant tumor progenitor cells characteristics
In this study, peritoneal cavity tumors mostly grew on the pancreas and mesentery after intraperitoneal inoculation of SKOV3 and OVCAR3 cells ( Figure 1A 
44
+ cells respectively sustained CD133 and CD44 expression ( Figure 1C ).
CD133 and CD44 expressions of ovarian ascites cells possessed stem-like characteristics
Self-renewal, clonogenic expansion, multilineage differentiation, enhanced tumorigenic potential, and chemoresistance are key characteristics of CSCs [17] . A fibronectin-rich niche supports mammary gland development and tumorigenesis; it augments cell proliferation [18] . To examine if PX1 subpopulations had the ability to proliferate under minimal environments, we tested the colony forming ability of SKOV3.PX1_133 
44
+ cells formed a number of colonies in media supplemented with 1% FBS, whereas the other types of cells formed few colonies (Figure 2A) Figure 2B-2C ). CD44 expression rather than CD133 expression conferred greater proliferative potential and self-renewal capacity.
We analyzed the differentiation potential of two cancer stem-like cells and found that when induced, cancer stem-like cells differentiated into adipocytes ( Figure 2D After paclitaxel treatment, the survival rates of each cell types in different culture conditions shown in Figure 3A . Proliferation reduced to 50 % when the drug concentration increased from 10 nM to 1000 nM. Figure 3B and Figure 3C ). 
Chemotactic capability of SKOV3.PX1_133+44+ cells
Tumors induced by SKOV3.PX1_133+44+ cells overexpress HER2
As shown by Ki-67 immunohistochemistry (IHC) staining, pancreatic and mesenteric ovarian tumors proliferated rapidly. According to the Hercep Test scoring system [19] , HER2 expression in ovarian ascites cells scored 3. By IHC staining, enhanced overexpression of HER2 was found in the tumors induced by the SKOV3. + cells demonstrated cancer stem-like cell characteristics. These ascites tumor derived cancer stemlike cells behaved similarly to the clinically advanced ovarian cancer, exhibiting oncogene overexpression, chemoresistance, tumorigenicity, and rapid metastasis.
Human primary-ovarian-cancer ascites cells are tumorigenic
Human primary-ovarian-cancer ascites cells and tumors were collected from patients with advanced ovarian cancer and ascites. Cells from cancer-cell spheres were subcultured to generate HOVCA_AS cells. Tumor formation was observed 150 days after implanting 1 × 10 5 HOVCA_AS cells into the dorsum of each female nude mouse ( Figure 5A ). > 150 > 1 Suspensions of four cell subsets 0.18 ml (6 × 10 4 /ml) were seeded into microtiter plates and incubated overnight in growth medium. Subsequently, cells were treated with chemotherapeutic drugs at various concentrations for 3 days. Finally, cells were treated with MTT, and the absorbance at 545 nm was measured in each well with a microplate reader (Molecular Devices, Eugene, OR, USA; reference: absorbance at 690 nm). Growth inhibition was estimated as follows: [1-(optical density of drug treatment/optical density of control)] × 100%. The IC 50 (50% growth inhibition) for a particular drug was estimated from a plot of drug concentration versus percentage growth inhibition. + conditioned medium at two and three hours). Cells were photographed at 100× magnification.
Next, human primary-ovarian-cancer tumors were homogenized, and a 0.1-mL aliquot of homogenate was subcutaneously transplanted to the dorsum each female nude mouse. Solid tumor formation was observed in 20 days and tumors grew to an average size of over 1000 mm 3 in 60 days. The homogenates from these tumors were injected intraperitoneally into nude mice. Ascites formation was observed after 35 days, and ascites tumor cells were collected and injected into the dorsa of nude mice. Notably, these ascites tumor cells formed tumors in 9 days compared to 20 days in those cells from primary tumor ( Figure 5B) . Tumorigenicity of the tumor cells from human primary ovarian cancers was enhanced after intraperitoneally injection into nude mice.
Human ovarian cancer ascites cells expressed more CD133 and CD44
Aggressive CSC populations evolve from primary CSCs through the acquisition of successive mutations [20] with late-stage tumors containing higher percentage of CSC populations [21] . Our results show that human ovarian cancer ascites cells significantly expressed more CD44-FITC (p < 0.005) and CD133-PE (p < 0.05), compared with primary ovarian tumors ( Figure 5C and 5D). Furthermore, they have a higher percentage of double positive (CD133 + , CD44 + ) cells than the primary tumors ( Figure 5E ). www.impactjournals.com/oncotarget
Candidate cluster of differentiation (CD) markers of cancer stem-like cells
Of the 336 surface markers tested, 60 CD markers were expressed in over 80% of the SKOV3.PX1_133 , 29 CD  markers (CD109, CD138, CD317, CD58, CD136, CD266,  CD47, CD95, HER2, CD277, CD324, CD344, CD239,  CD318, CD213a1, CD112, CD164, CD49a, CD71,  CD166, CD171, CD24, CD326, CD70, EGFR, + cells, are related to activation of the ITGB4-EGFR pathway which eventually promote cell proliferation [22] .
CD marker expression in human ascites CD133+CD44+ CSC-like cells
Using flow cytometry, we evaluated CD133 and CD44 expression in human primary-ovarian-cancer specimens (ascites cells, metastatic tumors, ovarian tumors, and normal ovary). CD133 and CD44 expression, alone or together, was the highest in human primaryovarian-cancer ascites cells. Furthermore, CD97, CD104, CD107a, CD121a, and CD307c were significantly more expressed in Ascites_133 +
44
+ cells than in ovarian or metastatic ovarian tumors (p < 0.005, p < 0.05, respectively; Figure 6D , 6E).
Overexpressed markers in Ascites_133+44+ cells possess ITGB4-EGFR pathway activating functions
CD97 enhances cell migration, activates proteolytic matrix metalloproteinases, and increases interleukin (IL)-8 secretion [23] and may be a target with which to modulate cancer progression [24, 25] . CD104 [integrin beta 4 (ITGB4)] mediates cell-matrix or cell-cell adhesion, enhances cell growth and signaling, and thus plays a pivotal role in cancer invasion [26] . CD107a (lysosomeassociated membrane glycoprotein 1), higher expressed in metastatic ovarian neoplasia, correlates with the metastatic potential [27] . CD121a (IL-1 receptor, type I) activates PIK3R1 and MYD88. The activation of TLR4/ MyD88/NF-κB signaling enhances aggressive tumor phenotype with poorer clinical outcome in epithelial ovarian cancer patients [28] [29] [30] CD133 expression correlated with a high grade of cell differentiation in human ovarian serous cystadenocarcinoma CD133 has been identified as a marker of enhanced proliferative potential in primary ovarian tumors [32] . We analyzed CD133 expression in 52 ovarian serous cystadenocarcinomas, stratified by grade of cell differentiation as the followings: grade I (10 samples, 19%), grade II (15 samples, 29%), and grade III (27 samples, 52%). Table 2 
44
+ cells that exhibited cancer stemlike characteristics, including self-renewal, multilineage differentiation, tumorigenicity, and chemoresistance. This procedure enriched the subpopulation of cancer stem-like cells. These similar phenomena apply to cells from human ovarian cancers.
CD133 is an 866-amino-acid single-chain transmembrane glycoprotein (molecular weight 120 kDa). It is expressed in CSCs isolated from brain, prostatic, pancreatic, colonic, and ovarian epithelial tumors [33] . Previous studies have shown that CD133 is expressed in primary tumors and that CD133-positive cells had high proliferative potential and exhibited clonogenic expansion [32] . CD44 is expressed in breast, prostate, colon, and ovarian tumors [34] . Higher CD44 expression is found in cancer stem cell population and confers chemoresistance [35] . CD44 expression enhances stemness characteristics, include differentiation, spheroids formation, and tumorigenicity.
In SKOV3 and OVCAR3 cells, about 90 % of cells express CD44 and 0.7 % of cells express CD133. And less than 1% expresses both CD133 and CD44. This finding is consistent with the fact that cancer stem-like cells or cancer stem cells are a small population of cancer cells www.impactjournals.com/oncotarget In Immunohistochemical analysis of CD133 expression in human ovarian serous cystadenocarcinoma tissues. CD133 expression correlated with tumor grade; specifically, a significant difference was observed between grades III and I. *1: (1 × number of score 1) + (2 × number of score 2) + (3 × number of score 3)/total number of grade I or II or III. *2: data are presented as mean CD133 scores ± SDs. Immunohistochemical analysis of CD133 expression in human ovarian serous cystadenocarcinoma tissues; 400× magnification. NOD mice) over a period of 3 months when injected subcutaneously, while intraperitoneal injection caused tumor and ascites formation and death of the animals. As shown in our tumor ascites model, the intraperitoneal injection augmented the cancer-stem like cells characteristics and caused the death of all the animals thus treated. This result further illustrates the possible intraperitoneal enrichment of cancer stem-like cells in the animals inoculated intraperitoneally.
The enrichment of cancer stem-like cells we have developed can benefit cancer study and potentially help the treatment of ovarian cancer. Hopefully it can be applied to other cancer types.
MATERIALS AND METHODS
Cell culture
The SKOV3 (ATCC HTB-77) and OVCAR3 (BCRC 60551) ovarian cancer cell lines respectively obtained from ATCC and BCRC and were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS). Cells were incubated at 37°C in a humidified incubator equilibrated with 5% CO 2 .
For sphere growth, those sorted cells were cultured in serum-free DMEM/F12 medium supplemented with 10 ng/ml human recombinant epidermal growth factor (EGF; Invitrogen, Carlsbad, USA), 10 ng/ml basic fibroblast growth factor (βFGF, Invitrogen), and 0.4% bovine serum albumin (BSA; Sigma-Aldrich) in ultra-low attachment plates (Corning ® ). The above culture medium was named CSLC culture medium. Culture medium was changed every 2 days after centrifuging the cultures at 300 g for 5 min to remove debris.
Culture of primary human ovarian cancer ascites cells
All studies were approved by the Institutional Review Board (IRB) of the Tri-Services General Hospital, Taipei, Taiwan. Ascites were collected from patients with ovarian cancer. Cells were collected after centrifugation at 300 g at 4°C for 10 minutes, and removal of red blood cells (RBCs) by Histopaque-1077 (Sigma). Cells were maintained in DMEM/F12 medium (Gibco) supplemented with 10% FBS and incubated at 37°C in a humidified atmosphere equilibrated with 5% CO 2 . These cells were named HOVCA_AS cells. Spheres grown from these HOVCA_AS cells were maintained in stem-like cells culture medium.
Primary human ovarian cancer specimens
Clinical ovarian cancer samples (ovarian tumors and metastatic tumors) were washed with normal saline, minced (< 5 mm in size) and disassociated with Accutase TM (eBioscience) at 37°C for 30 minutes and centrifuged at 300 g at 4°C for 10 minutes. Disassociated cells were obtained after removing supernatant and resuspension in medium with 10% FBS supplement, and then filtered through 40 mm cell strainers (BD Falcon).
Ovarian cancer ascites formation in immune incompetent mice
All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the National Defense Medical Center, Taipei, Taiwan. Suspensions of SKOV3 cells at a density of 5 × 10 6 /0.2 ml in Dulbecco's phosphate buffered saline (DPBS) were injected intraperitoneally into five female nude mice. Mice were initially observed twice weekly for signs of ascites formation after tumor development -abdominal bloating, loss of subcutaneous fat, hunched posture, and decreased movement and then followed up every two days before sacrifice of the animals. The intraperitoneal tumors were removed after sacrifice of the mice. After sieving the minced tumor debris (BD strainer, 40 μm), the tumor cells were harvested and were cultured.
These tumor cells collected from these ascites cells were named SKOV3.PX1 and OVCAR3.PX1. These ascites cells were labeled with CD44-fluorescein isothiocyanate (FITC) and CD133-phycoerythrin (PE) respectively, and + were maintained in stem-like cells culture medium. These cells formed non-adherent spheres under these conditions. The culture medium was changed every 2 days after centrifuging at 300 g for 5 min to remove debris.
Tumorigenicity
All animal experiments were approved by the IACUC of the National Defense Medical Center, Taipei, Taiwan. The SKOV3.PX1_133 +
44
+ cell were collected after dispersing the cell spheres with Accutase TM (Biolegend) and then washed with DPBS, and centrifuged at 300 g. Suspensions of 1 × 10 5 or 1 × 10 4 cells in 0.1 ml DPBS were injected subcutaneously into the right flank of SCID/NOD female mice under aseptic conditions. The tumor size was estimated by the products of the length and width of the subcutaneous tumors. The growth of these tumors was monitored for 3-6 months after injection.
Chemoresistance assay
MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) cytotoxicity assay was used to evaluate the growth inhibition induced by chemotherapeutic drugs in various cells. Drugs were dissolved in dimethyl sulfoxide (DMSO; Sigma, D8779) to prepare stock solutions and were serially diluted with DPBS before use. MTT assays were performed as described by Wang et al. [37] . Briefly, cell suspensions were prepared from the monolayer cultures, seeded into microtiter plates (Nunc), and incubated in growth medium overnight. Cells were then treated with chemotherapeutic drugs at various concentrations for 3 days. Next, cells were treated with MTT and the absorbance at 545 nm was measured with a microplate reader (microplate reader, Molecular Device) using absorbance at 690 nm as a reference. Growth inhibition was estimated according to the following formula: [1-(optical density of drug treatment/optical density of control)] × 100%. The IC 50 (for 50% growth inhibition) for a particular drug was estimated using a plot of drug concentration versus percentage growth inhibition.
Adhesion assay
Suspensions of 12,000 cells were seeded into a 6-cm dish coated with fibronectin and cultured in medium containing 1% and 5% FBS medium 
Colony formation assay
Suspensions of 12,000 cells were plated onto fibronectin-coated 6-cm dishes and cultured in medium containing 1% and 5% FBS. Thus, the cultured cell types included SKOV3 and OVCAR3, CD44 positive cells, CD133 positive cells, and CD44 & CD133 double positive cells. Colony formation was monitored between days 1 to 8 after seeding, and the colonies were stained using crystal violet on the eighth day.
Adipogenic differentiation assay
The SKOV3.PX1_133 ) were seeded into 6-cm dishes and cultured in induction medium. The adipogenic induction medium consisted of 5% FBS, 1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 5 µg/ml insulin, and 60 µM indomethacin. The culture medium was changed every 3 to 4 days. After 10 days of differentiation, cells were fixed with 10% formaldehyde and stained with oil red O for the detection of adipocytes.
Chemotaxis assay
For the chemotaxis assay, 100 μl of SKOV3.PX1 cells (5 × 10 5 cells/mL in a serum-free medium) were added to the upper decks of the transwells 600 μl condition medium of SKOV3.PX1 and SKOV3.PX1_133 
44
+ cells (two cells respectively were cultured with serum-free medium for 24 h as the condition medium) was added to the lower decks. It was observed that the SKOV3.PX1 cells migrated from the upper deck to the lower deck over a 1-3-h period. The movement across the transwell membrane was observed at 1, 2, and 3 h.
Surface marker expression detected by flow cytometry
Cells were harvested and washed with phosphate buffered saline (PBS) containing 2% FBS from flasks, centrifuged at 300 g at 4°C for 5 min and the cell pellets were collected. We adjusted the cell density to 2.5-3 × 10 6 cells per assay for the flow cytometry assay. For the cells labeled with fluorochrome antibodies, the experimental procedures followed a standard protocol. Finally, cell pellets were added to a fixation buffer (BD) 100-µl stand at 4°C for 20 min, and then stored at 4°C without light until flow cytometry analysis (BD). Viable cells were identified using the CellQuest software, and the data are shown as logarithmic histograms.
RNA isolation and reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNAs were extracted using TRIzol solution (Invitrogen). cDNA was prepared by incubation of a mixture of 20 μl at 37°C for 1 hour, which contained 2 μg total RNA, 1 μl Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI), 1 μl deoxyribonucleotide triphosphate, 1 μl oligo-dT and 1 U RNase recombinant RNase inhibitor. Polymerase chain reaction (PCR) was performed in 20 μl of a reaction mixture containing 400 ng cDNA and 500 nM each of nanog (sense: 5′-CAAAGGCAAAC AACCCACTT-3′ and antisense: 5′-TCTGCTGGAGGCTGAGGTAT-3′), or beta-actin (sense: 5′ -AGGCGGACTATGACTTAGTTGCGTTACACC-3′ and antisense: 5′-AAGTC CTCGGCCACATTGTGAACTTTG -3′) primers. The PCR products were quantified using a 2% (w/v) agarose gel electrophoresis that was stained with 0.015% RedSafe (iNtRON).
IHC staining
Paraffin-embedded sections of malignant ovarian epithelial tumors and normal ovarian tissues were stained for CD44 and HER2. These tissue sections of normal ovaries and ovarian serous cystadenocarcinomas were obtained from Pantomics (GenDiscovery Biotechnology, tissue serial no. OVC2281). Briefly, after the paraffin was removed by xylene, the sections were rehydrated in a series of ethanol solutions with decreasing alcohol concentrations, and then washed in PBS. Sections were incubated with the primary antibody for 1 to 2 hours, washed with TBST, and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour. Following this, sections were counterstained with hematoxylin. Images of the sections were taken using a microscope equipped with standard optics, and were digitalized. Immunostaining was scored by at levels 1 to 3 for CD44 and CD133 expressions according to the commercial Hercep Test scoring system [19] .
Statistical analyses
All data are shown as mean ± SEM from three independent experiments. The statistical significance of the data was determined using Student's t-test, P-values < 0.05 were recognized as significant and marked with '*'. 
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